CSBio CSBio

X
[{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Behring to Acquire Biotech Company Vitaeris","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Vitaeris"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Evolve Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolve Biologics\u00ae Completes Phase III Adult and Pediatric Trials for Plasmacap\u2122 Ig (Intravenous Immunoglobulin)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Evolve Biologics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCap IG in adults and children with primary immune deficiency disease met all primary and secondary endpoints.

            Lead Product(s): Human Immunoglobulin

            Therapeutic Area: Immunology Product Name: PlasmaCap IG

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis.

            Lead Product(s): Voclosporin

            Therapeutic Area: Immunology Product Name: ISA247

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care.

            Lead Product(s): Voclosporin,Mycophenolate Mofetil

            Therapeutic Area: Immunology Product Name: ISA247

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            With this acquisition, clazakizumab joins CSL842 and CSL964 as part of CSL Behring’s portfolio of products in late-stage development to address significant unmet needs in the transplant community.

            Lead Product(s): Clazakizumab

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: CSL

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY